| Assessment Status | Rapid Review Complete |
| HTA ID | 22045 |
| Drug | Nivolumab |
| Brand | Opdivo® |
| Indication | Nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC) with tumour cell PD-L1 (programmed death ligand 1) expression ≥1%. |
| Assessment Process | |
| Rapid review commissioned | 01/07/2022 |
| Rapid review completed | 29/07/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
The HSE has approved reimbursement following confidential price negotiations. July 2023
